Page last updated: 2024-12-05

nandrolone decanoate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Nandrolone decanoate is a synthetic anabolic-androgenic steroid (AAS) that is used to treat certain medical conditions, such as anemia and osteoporosis. It is also used illegally to increase muscle mass and performance in athletes. Nandrolone decanoate is a long-acting ester of nandrolone, a synthetic testosterone derivative. The decanoate ester prolongs the drug's half-life, allowing for less frequent injections. Nandrolone decanoate is synthesized by esterifying nandrolone with decanoic acid. The synthesis process involves several steps, including the reaction of nandrolone with decanoic acid chloride in the presence of a base. Nandrolone decanoate works by binding to androgen receptors in the body. This binding stimulates the production of proteins, which can lead to increased muscle mass and bone density. Nandrolone decanoate also has other effects, such as promoting red blood cell production and decreasing bone resorption. Nandrolone decanoate is studied for its potential therapeutic uses, such as treating anemia, osteoporosis, and certain types of cancer. It is also studied for its effects on muscle growth and athletic performance. However, nandrolone decanoate has several side effects, including liver damage, acne, and mood swings. It is important to use nandrolone decanoate only under the supervision of a qualified healthcare professional.'

Nandrolone Decanoate: Decanoic acid ester of nandrolone that is used as an anabolic agent to prevent or treat WASTING SYNDROME associated with severe chronic illness or HIV infection (HIV WASTING SYNDROME). It may also be used in the treatment of POSTMENOPAUSAL OSTEOPOROSIS. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9677
CHEMBL ID1200946
CHEBI ID7467
SCHEMBL ID27975
MeSH IDM0044317

Synonyms (95)

Synonym
(17beta)-3-oxoestr-4-en-17-yl decanoate
retabolyl
estr-4-en-3-one, 17-((1-oxodecyl)oxy)-, (17beta)-
17beta-hydroxyestr-4-en-3-one decanoate
17-beta-hydroxyestr-4-en-3-one decanoate
estr-4-en-3-one, 17-beta-hydroxy-, decanoate
ziremilon
drg 0264
einecs 206-639-3
17beta-hydroxyestr-4-en-3-one 17-decanoate
anaboline depot
hybolin decanoate
19-norandrostenolone decanoate
(17-beta)-17-((1-oxodecyl)oxy)estr-4-en-3-one
palactin
naboline
brn 2228051
ndrolone-d
19-nortestosterone decanoate
superbolan
nortestosterone decanoate
salistoperm
dimapolan
norandrostenolone decanoate
rougerol
anabolin depot
17 beta-hydroxyestr-4-en-3-one 17-decanoate
C08154
360-70-3
nandrolone decanoate
estr-4-en-3-one, 17-[(1-oxodecyl)oxy]-, (17.beta.)-
19-nortestosterone-17.beta.-decanoate
retabolil
deca-durobolin
deca-hybolin
[(8r,9s,10r,13s,14s,17s)-13-methyl-3-oxo-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl] decanoate
NCGC00159403-02
D00955
nandrolone decanoate (jan/usp)
deca-durabolin (tn)
nandrolone 17beta-decanoate
DB08804
nandrolone decanoate ciii
CHEMBL1200946
chebi:7467 ,
NCGC00159403-04
h45187t098 ,
nandrolone decanoate [usan:usp:jan]
unii-h45187t098
cas-360-70-3
dtxsid7023352 ,
tox21_111638
dtxcid203352
A823112
nandrolone decanoate [vandf]
nandrolone decanoate [orange book]
17b-hydroxyestr-4-en-3-one decanoate.
nandrolone decanoate [mi]
nandrolone decanoate ciii [usp-rs]
nandrolone decanoate [jan]
17.beta.-hydroxyestr-4-en-3-one 17-decanoate
estr-4-en-3-one, 17-((1-oxodecyl)oxy)-, (17.beta.)-
nandrolone decanoate [who-dd]
nandrolone decanoate [ep monograph]
nandrolone decanoate [usp monograph]
nandrolone decanoate [usan]
nandrolone decanoate [ep impurity]
nandrolone decanoate [mart.]
AKOS025311438
SCHEMBL27975
tox21_111638_1
NCGC00263561-01
CS-4613
JKWKMORAXJQQSR-MOPIKTETSA-N
estr-4-en-3-one, 17-[(1-oxodecyl)oxy]-, (17b)-
HY-13698
(1s,2r,10r,11s,14s,15s)-15-methyl-5-oxotetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-6-en-14-yl decanoate
GS-3155
AC-1484
(8r,9s,10r,13s,14s,17s)-13-methyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl decanoate
nandrolone decanoate, united states pharmacopeia (usp) reference standard
nandrolonedecanoate
nandrolone decanoate, european pharmacopoeia (ep) reference standard
nandrolone decanoate for peak identification, european pharmacopoeia (ep) reference standard
nandrolone decanoate for system suitability, european pharmacopoeia (ep) reference standard
19-nortestosterone 17-decanoate
mfcd00135100
Q16634231
17 beta hydroxyestr 4 en 3 one 17 decanoate
nandrolone decanoate (ep monograph)
nandrolone decanoate (usan:usp:jan)
nandrolone decanoate ciii (usp-rs)
nandrolone decanoate (ep impurity)
nandrolone decanoate (mart.)
nandrolone decanoate (usp monograph)

Research Excerpts

Overview

Nandrolone decanoate (ND) is an anabolic-androgenic steroid. Its indiscriminate use leads to subclinical alterations in the hypothalamic-pituitary-gonadal axis and androgen-dependent organs.

ExcerptReferenceRelevance
"Nandrolone decanoate (ND) is a commonly used anabolic-androgenic steroid. "( Cynara scolymus leaves extract alleviates nandrolone decanoate-induced alterations in testicular function and sperm quality in albino rats.
Abdel-Daim, MM; Aleya, L; Mohammed, ET; Radi, AM, 2020
)
2.27
"Nandrolone decanoate (ND) is a potent anabolic steroid have many clinical indications, but not investigated in burn injuries yet."( Nandrolone decanoate safely combats catabolism in burned patients: A new potential indication after recall.
Ali, T; Ali, YH, 2022
)
2.89
"Nandrolone decanoate (ND) is an anabolic-androgenic steroid, and its indiscriminate use leads to subclinical alterations in the hypothalamic-pituitary-gonadal axis and androgen-dependent organs."( Nandrolone decanoate and resistance exercise affect prostate morphology and hormone receptor interface in adult rats with implications for the aging process.
Chuffa, LGA; de Melo-Neto, JS; Domeniconi, RF; Fávaro, WJ; Gomes, FC; Pinheiro, PFF; Scarano, WR, 2020
)
3.44
"Nandrolone decanoate is an anabolic androgenic steroid that is abused worldwide by young athletes and bodybuilders to enhance their physical performance. "( Lycopene protects against renal cortical damage induced by nandrolone decanoate in adult male rats.
El Shaer, DF; Shalaby, AM, 2019
)
2.2
"Nandrolone Decanoate (ND) is an Anabolic Androgenic Steroid (AAS) that under abusive regimen can lead to multiple physiological adverse effects. "( Long-term treatment with Nandrolone Decanoate impairs mesenteric vascular relaxation in both sedentary and exercised female rats.
Bernabe, CS; Bissoli, NS; Brasil, GA; Caliman, IF; de Andrade, TU; de Lima, EM; de Melo, AF; do Nascimento, AM; Figueiredo, SG, 2017
)
2.2
"Nandrolone decanoate (ND) is an anabolic steroid, modified to enhance anabolic rather than androgenic actions. "( Effect of anabolic steroid nandrolone decanoate on the properties of certain enzymes in the heart, liver, and muscle of rats, and their effect on rats' cardiac electrophysiology.
Kawalko, A; Sokolska, J; Strumilo, S; Tylicki, A, 2007
)
2.08
"Nandrolone decanoate (ND) is an anabolic steroid with a positive effect on bone mass in osteoporotic patients. "( Mechanical properties, bone mineral content, and bone composition (collagen, osteocalcin, IGF-I) of the rat femur: influence of ovariectomy and nandrolone decanoate (anabolic steroid) treatment.
Aerssens, J; Dequeker, J; Geusens, P; Osman, AA; Schot, LP; Van Audekercke, R, 1993
)
1.93

Effects

Nandrolone decanoate has no effect on the SRE, VO2max and VO2submax of untrained rats. It has beneficial effects on weight, lean body mass and quality of life in selected patients with mild to moderate HIV wasting.

ExcerptReferenceRelevance
"Nandrolone decanoate has no effect on the SRE, VO2max and VO2submax of untrained rats. "( Effects of nandrolone decanoate on VO2max, running economy, and endurance in rats.
Boyadjiev, NP; Georgieva, KN, 2004
)
2.16
"Nandrolone decanoate has beneficial effects on weight, lean body mass and quality of life in selected patients who have mild to moderate HIV wasting."( Safety and efficacy of nandrolone decanoate for treatment of wasting in patients with HIV infection.
Allen, BJ; Bodsworth, NJ; Finlayson, R; Furner, VL; Gold, J; High, HA; Li, Y; Michelmore, H; Oliver, CJ, 1996
)
2.05

Actions

Nandrolone decanoate does not enhance the response rate to this rHuEpo dose and is associated with significant side effects.

ExcerptReferenceRelevance
"Nandrolone decanoate does not produce significant effect on femur, exception on its distal extremity at late period. "( Effects of nandrolone decanoate on femur morphology. Experimental study.
Brasil, FB; Félix-Patrício, B; Marchon, RG; Souza, DB, 2021
)
2.45
"Nandrolone decanoate does not enhance the response rate to this rHuEpo dose and is associated with significant side effects."( A controlled trial of recombinant human erythropoietin and nandrolone decanoate in the treatment of anemia in patients on chronic hemodialysis.
Berns, JS; Cohen, RM; Rudnick, MR, 1992
)
1.25

Treatment

Nandrolone decanoate (ND) treatment had no effect on the MAP (CON=105+/-5; DECA=110+/-3 mmHg). Pretreatment with nandrolones prevented depression in tumor-bearing mice and increased MPS activities of normal or tumor- bearing mice above the level of non-treated normal mice.

ExcerptReferenceRelevance
"Nandrolone decanoate treatment increased MAP (CON=99+/- 1 mmHg; DECA=109+/-2 mmHg; p<0.01) but did not change the mean basal HR (CON=356+/-13 bpm; DECA=367+/-11 bpm)."( Long-term treatment with supraphysiological doses of nandrolone decanoate reduces the sensitivity of Bezold-Jarisch reflex control of heart rate and blood pressure.
Abreu, GR; Bissoli, NS; Busato, VC; de Andrade, TU; Jarske, RD; Medeiros, AR; Moysés, MR; Santos, MC, 2009
)
1.32
"Nandrolone decanoate treatment increased the QTc interval and reduced the parasympathetic indexes of HRV (RMSSD, pNN5 and high-frequency power) in sedentary and trained rats. "( The blockade of angiotensin AT1 and aldosterone receptors protects rats from synthetic androgen-induced cardiac autonomic dysfunction.
da H Silva, A; dos Santos, MC; Ferraz, EF; Marques Neto, SR; Nascimento, JH, 2013
)
1.83
"Nandrolone decanoate pre-treatment of suspended animals (nandrolone decanoate hindlimb-unweighted vs."( Nandrolone decanoate pre-treatment attenuates unweighting-induced functional changes in rat soleus muscle.
Bigard, X; Bouhlel, A; Joumaa, WH; Léoty, C, 2002
)
2.48
"Nandrolone decanoate treatment thus affects Ca (2+) uptake by the SR in a fibre-type dependent manner."( Nandrolone decanoate treatment affects sarcoplasmic reticulum Ca(2+) ATPase function in skinned rat slow- and fast-twitch fibres.
Bouhlel, A; Joumaa, WH; Léoty, C, 2003
)
2.48
"Nandrolone decanoate treatment resulted in greater increases in fat-free mass than placebo and demonstrated a trend for a significant increase when compared with testosterone."( Effects of nandrolone decanoate compared with placebo or testosterone on HIV-associated wasting.
Aiuti, F; Batterham, MJ; Bloch, M; Danner, SA; Falleiros Carvalho, LH; Gatell, J; Gazzard, B; Geurts, TB; Gold, J; Harms, MK; Helmyr, PM; Horban, A; Lee, C; Panos, G; Phanuphak, P; Pinchera, A; Prasithsirikul, W; Rekers, H; Silva de Mendonça, J, 2006
)
1.45
"Nandrolone decanoate (ND) treatment had no effect on the MAP (CON=105+/-5; DECA=110+/-3 mmHg). "( Higher physiological doses of nandrolone decanoate do not influence the Bezold-Jarish reflex control of bradycardia.
Abreu, GR; Andrade, TU; Bissoli, NS; Busato, VC; Medeiros, AR; Moysés, MR; Santos, MC, 2008
)
2.08
"Pretreatment with nandrolone decanoate prevented such depression in tumor-bearing mice and increased MPS activities of normal or tumor-bearing mice above the level of non-treated normal mice."( Restorative effects of nandrolone decanoate on the mononuclear phagocyte system in tumor-bearing mice.
Nomoto, K; Ohhara, R; Sanui, H; Takeya, K; Yoshida, S, 1981
)
0.9
"Treatment with nandrolone decanoate was found to restore the loss in carbonate, where the resulting mineral had a larger quantity of type B carbonate."( Characterization of bone mineral composition in the proximal tibia of cynomolgus monkeys: effect of ovariectomy and nandrolone decanoate treatment.
Carlson, CS; Chance, MR; Huang, RY; Miller, LM, 2002
)
0.86

Toxicity

Pre-treatment with the anabolic steroid nandrolone decanoate (ND) increases the LD50 of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) and 5-Fluorouracil (FU) in NMRI mice. Study proposes that nandrole could be used in safe and effective way to combat hypercatabolic impact in burn injury.

ExcerptReferenceRelevance
"Pre-treatment with the anabolic steroid nandrolone decanoate (ND) increases the LD50 of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) and 5-Fluorouracil (FU) in NMRI mice."( Effects of nandrolone decanoate on the toxicity and anti-tumour action of CCNU and FU in murine tumours.
Bibby, MC; Double, JA; Mughal, MA, 1981
)
0.92
" No adverse effect of anabolic steroid administration was evident."( The effect of anabolic steroids on ameliorating the adverse effects of chronic corticosteroids on intestinal anastomotic healing in rabbits.
Buchmiller, TL; Fonkalsrud, EW; Kim, CS; Phillips, JD, 1993
)
0.29
" The high doses misused are associated with numerous adverse effects."( Impact of nandrolone decanoate on gene expression in endocrine systems related to the adverse effects of anabolic androgenic steroids.
Alsiö, J; Bergström, L; Birgner, C; Björkblom, L; Isaksson, P; Lindblom, J; Schiöth, HB, 2009
)
0.76
" Both clinical findings and laboratory findings are correlated and highly support the use of ND in burns as new effective and safe long-lasting indication."( Nandrolone decanoate safely combats catabolism in burned patients: A new potential indication after recall.
Ali, T; Ali, YH, 2022
)
2.16
" Study proposes that nandrolone decanoate could be used in safe and effective way to combat hypercatabolic impact in burn injury."( Nandrolone decanoate safely combats catabolism in burned patients: A new potential indication after recall.
Ali, T; Ali, YH, 2022
)
2.48
" Our research was directed to assess the toxic effects of anabolic steroids on cardiac and skeletal muscles in male albino rats and to evaluate the potential ameliorative effects of fenugreek seeds extract and silymarin."( The toxic effects of anabolic steroids "nandrolone decanoate" on cardiac and skeletal muscles with the potential ameliorative effects of silymarin and fenugreek seeds extract in adult male albino rats.
Abdelmenem, A; Alim, MAA; Ghaleb, SS; Hassan, DAE; Nabil, S; Zaki, AR, 2023
)
1.18
"The anabolic steroids toxic effects on rats showed a significant decrease in serum High Density Lipoprotein (HDL) level and increase in cholesterol, triglycerides, and Low-Density Lipoprotein (LDL) levels."( The toxic effects of anabolic steroids "nandrolone decanoate" on cardiac and skeletal muscles with the potential ameliorative effects of silymarin and fenugreek seeds extract in adult male albino rats.
Abdelmenem, A; Alim, MAA; Ghaleb, SS; Hassan, DAE; Nabil, S; Zaki, AR, 2023
)
1.18
"Anabolic steroids have a toxic effect on the cardiac and skeletal muscles of albino rats with improvement by treatment with fenugreek seeds extract and silymarin."( The toxic effects of anabolic steroids "nandrolone decanoate" on cardiac and skeletal muscles with the potential ameliorative effects of silymarin and fenugreek seeds extract in adult male albino rats.
Abdelmenem, A; Alim, MAA; Ghaleb, SS; Hassan, DAE; Nabil, S; Zaki, AR, 2023
)
1.18

Pharmacokinetics

ExcerptReferenceRelevance
" The serum levels of nandrolone (19-nortestosterone) were determined by radioimmunoassay and used to estimate pharmacokinetic parameters."( Pharmacokinetic parameters of nandrolone (19-nortestosterone) after intramuscular administration of nandrolone decanoate (Deca-Durabolin) to healthy volunteers.
Bosch, AM; Donker, CW; Wijnand, HP, 1985
)
0.49
" The method was used to measure serum concentrations of NT, T and DHT in a pharmacokinetic study and in a clinical trial for male fertility control."( Pharmacokinetics of 19-nortestosterone esters in normal men.
Belkien, L; Gunnarsson, PO; Hano, R; Nieschlag, E; Schürmeyer, T, 1985
)
0.27

Compound-Compound Interactions

ExcerptReferenceRelevance
"Fifty RA patients receiving prednisolone and prednisolone combined with retabolil were examined."( [Experimental substantiation of the treatment of patients with rheumatoid arthritis with prednisolone and its combination with retabolil (clinico-experimental study)].
Bagirova, VV; Iaglinskiĭ, VA; Kriukov, AP, 1986
)
0.27
"The authors report on the experience with amino acid drugs ( alvesin -new, aminon ) used in combination with anabolic steroids (retabolil) in patients with acute myocardial infarctions."( [Clinical efficacy of using amino acids in combination with anabolic steroids for the purpose of limiting the size of a myocardial infarct].
Leshchinskiĭ, LA; Vtorov, AE, 1984
)
0.27
" Therefore, we conducted a 6-month, prospective, randomized trial comparing low-dose rHuEPO alone and in combination with androgens for the treatment of the anemia of end-stage renal failure."( A 6-month study of low-dose recombinant human erythropoietin alone and in combination with androgens for the treatment of anemia in chronic hemodialysis patients.
Buhsmer, JP; Burke, JF; Dunn, SR; Gaughan, WJ; Liss, KA; Mangold, AM; Michael, B, 1997
)
0.3
"The aim of this study was to evaluate the expression of key genes responsible for tendon remodeling of the proximal and distal regions of calcaneal tendon (CT), intermediate and distal region of superficial flexor tendon (SFT) and proximal, intermediate and distal region of deep flexor tendon (DFT) submitted to 7 weeks of jumping water load exercise in combination with AAS administration."( Gene expression in distinct regions of rat tendons in response to jump training combined with anabolic androgenic steroid administration.
Carvalho, HF; de Andrade Perez, SE; Durigan, JL; Heinemeier, KM; Kjaer, M; Marqueti, RC; Marqueti, Rde C; Schjerling, P; Selistre-de-Araujo, HS, 2012
)
0.38
" The purpose of this study is to verify the effect of early administration of an anabolic steroid in combination with vitamin D on the process of bone healing in polytrauma patients."( [Administration of Anabolic Steroids in Combination with Vitamin D in the Early Stage of Treatment of Polytrauma Patients - a Dead End?]
Divák, J; Ječmínek, V; Ječmínková, R; Káňová, M; Pleva, L; Vrtková, A, 2021
)
0.62

Bioavailability

ExcerptReferenceRelevance
" In order to make sure about the adequacy of doses and bioavailability of drug, testes parameters were also considered."( Chronic administration of nandrolone decanoate does not increase the plasma homocysteine level of male rats.
Golbahar, J; Mirkhani, H; Shokri, S, 2005
)
0.63
" The absorption rate constant of compounds is found to be related to the logP of the solubilized prodrug."( Fundamental understanding of drug absorption from a parenteral oil depot.
Kalicharan, RW; Schot, P; Vromans, H, 2016
)
0.43
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Male hamsters of an inbred strain carrying a genetic trait for cardiomyopathy were dosed by sc injection weekly with an anabolic-androgenic steroid. Knowing that the half-life for nandrolone decanoate in man is similar to that in rats, theoretical considerations are given with a number of dosing schemes.

ExcerptRelevanceReference
" Knowing that the half-life for nandrolone decanoate in man is similar to that in rats, theoretical considerations are given with a number of dosing schemes."( Implications of basic pharmacology in the therapy with esters of nandrolone.
van der Vies, J, 1985
)
0.55
"Male hamsters of an inbred strain carrying a genetic trait for cardiomyopathy were dosed by sc injection weekly with an anabolic-androgenic steroid, nandrolone decanoate, beginning when 3 months old."( Nandrolone decanoate reduces the premature mortality of cardiomyopathic hamsters.
Davis, WM; Lin, TL; Long, SF, 1993
)
1.93
", reduction of bone resorption and/or stimulation of bone formation), the ultimate effect on mechanical properties, and the most effective dosage are not yet clear."( Mechanical properties, bone mineral content, and bone composition (collagen, osteocalcin, IGF-I) of the rat femur: influence of ovariectomy and nandrolone decanoate (anabolic steroid) treatment.
Aerssens, J; Dequeker, J; Geusens, P; Osman, AA; Schot, LP; Van Audekercke, R, 1993
)
0.49
" The authors reported that this study is the first to quantify the dose-response characteristics of individual AAS compounds with regard to these behavioral and endocrine measures."( Comparison of the effects of 17 alpha-methyltestosterone, methandrostenolone, and nandrolone decanoate on the sexual behavior of castrated male rats.
Clark, AS; Fast, AS, 1996
)
0.52
" In order to evaluate the anabolic or toxic effects of the dosing regimens used, selected peripheral effects were monitored as well."( The effect of sub-chronic nandrolone decanoate treatment on dopaminergic and serotonergic neuronal systems in the brains of rats.
Ellermaa, S; Kankaanpää, A; Karila, T; Kurling, S; Seppälä, T, 2005
)
0.63
"If goals of future studies are to improve body composition, dosing of ND up to 200 mg/week in males and 50 mg/week in females should be investigated."( Nandrolone decanoate as anabolic therapy in chronic kidney disease: a randomized phase II dose-finding study.
Ahmed, W; Jibani, MM; Kumwenda, MJ; Lemmey, AB; Macdonald, JH; Marcora, SM, 2007
)
1.78
" The day after the last injection, the dose-response to ISO (1 x 10(-8), 5 x 10(-8) and 10(-7)M), was studied in isolated rat hearts harvested from unstressed animals (unstressed+vehicle (control) or unstressed+ND) or from stressed animals (stressed+vehicle or stressed+ND): acute stress protocol consisted in restrain for 1h immediately before sacrifice."( Nandrolone-pretreatment enhances cardiac beta(2)-adrenoceptor expression and reverses heart contractile down-regulation in the post-stress period of acute-stressed rats.
Abbadessa, G; Mancardi, D; Pagliaro, P; Penna, C; Racca, S; Spaccamiglio, A, 2007
)
0.34
" Supra-physiological dosage of ND negatively reverses the effects of exercise on the cardiac muscle expression of sarcolemmal, but not mitochondrial, K(ATP) channel subunits."( Nandrolone decanoate negatively reverses the beneficial effects of exercise on cardiac muscle via sarcolemmal, but not mitochondrial K(ATP) channel.
Bayat, G; Goudarzvand, M; Hajizadeh, S; Javan, M; Khalili, A; Safari, F; Salimi, M; Shokri, S, 2016
)
1.88
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
steroid ester
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (19)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Ferritin light chainEquus caballus (horse)Potency15.84895.623417.292931.6228AID485281
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency26.83253.189029.884159.4836AID1224846
USP1 protein, partialHomo sapiens (human)Potency44.66840.031637.5844354.8130AID504865
Microtubule-associated protein tauHomo sapiens (human)Potency7.50590.180013.557439.8107AID1460; AID1468
AR proteinHomo sapiens (human)Potency2.91180.000221.22318,912.5098AID743036; AID743040; AID743042; AID743053; AID743054
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency3.46710.01237.983543.2770AID1645841
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency9.52050.000214.376460.0339AID720692
retinoid X nuclear receptor alphaHomo sapiens (human)Potency15.94340.000817.505159.3239AID1159527; AID1159531
pregnane X nuclear receptorHomo sapiens (human)Potency18.83360.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency0.79730.000229.305416,493.5996AID743069; AID743075; AID743077; AID743079
GVesicular stomatitis virusPotency12.30180.01238.964839.8107AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency30.90080.00108.379861.1304AID1645840
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency24.65370.023723.228263.5986AID743222; AID743241
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency0.13330.001723.839378.1014AID743083
lamin isoform A-delta10Homo sapiens (human)Potency12.58930.891312.067628.1838AID1487
Interferon betaHomo sapiens (human)Potency12.30180.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency12.30180.01238.964839.8107AID1645842
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency12.30180.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency12.30180.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (45)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (18)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (22)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (39)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (530)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990136 (25.66)18.7374
1990's109 (20.57)18.2507
2000's123 (23.21)29.6817
2010's129 (24.34)24.3611
2020's33 (6.23)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 77.49

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index77.49 (24.57)
Research Supply Index6.49 (2.92)
Research Growth Index4.55 (4.65)
Search Engine Demand Index140.27 (26.88)
Search Engine Supply Index2.04 (0.95)

This Compound (77.49)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials92 (16.23%)5.53%
Reviews16 (2.82%)6.00%
Case Studies35 (6.17%)4.05%
Observational0 (0.00%)0.25%
Other424 (74.78%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (12)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Nandrolone Decanoate Therapy and Therapy With Complex Physiotherapy and Diet in the Treatment of Sarcopenia [NCT05978206]Phase 2168 participants (Anticipated)Interventional2023-08-10Recruiting
Preliminary Effect and Safety of Physiotherapy With Strength Training and Protein-rich Nutritional Supplement in Combination With Anabolic Steroids in Cross-continuum Rehabilitation of Patients With Hip Fracture - a Randomized Controlled Pilot Trial. (The [NCT03545347]Phase 229 participants (Actual)Interventional2018-09-03Completed
Single Dose, Dose-Ranging Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics Study of 11-β Methyl Nortestosterone Dodecylcarbonate (11β-MNTDC) in Healthy Men [NCT02754687]Phase 112 participants (Actual)Interventional2016-04-30Active, not recruiting
The Efficacy of Anabolic Steroids for the Nutritional Rehabilitation of Critically Ill Patients [NCT00242463]Phase 220 participants (Anticipated)Interventional2005-10-31Terminated(stopped due to drug no longer available in canada)
Assessment of the Treatment of the Severely Burned With Anabolic Agents on Clinical Outcomes, Recovery and Rehabilitation [NCT00675714]Phase 2/Phase 31,126 participants (Actual)Interventional2004-01-31Terminated(stopped due to At the request of the study site, this study has been closed and access to study-related data is unavailable. We are unable to submit the results-data.)
Male Hormones for Telomere Related Diseases [NCT02055456]Phase 1/Phase 220 participants (Actual)Interventional2014-02-01Completed
Anabolic Steroids and Exercise in Hemodialysis Patients [NCT00250536]80 participants Interventional2000-03-31Completed
Role of Anabolic Steroid and Propranolol in Paediatric Burn- A Randomized Controlled Trial [NCT05805553]114 participants (Anticipated)Interventional2020-12-01Recruiting
[NCT00000597]Phase 30 participants Interventional1982-03-31Completed
A Randomized, Double-Blind, Placebo-Controlled, Phase I/II Trial of Nandrolone Decanoate in Women With HIV-Associated Weight Loss [NCT00000854]Phase 138 participants InterventionalCompleted
28-Day Repeat-Dose, Dose Escalation Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics Study of 11-β Methyl Nortestosterone Dodecylcarbonate (11β-MNTDC) in Healthy Men [NCT03298373]Phase 143 participants (Actual)Interventional2017-11-09Active, not recruiting
Impact of the Use of Nandrolone on the Treatment of Malnutrition Induced by Cancer [NCT03263520]60 participants (Actual)Interventional2016-02-29Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]